Plain-English translation of NCT06892093 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
Neratinib is a targeted cancer medication that helps treat HER2-positive breast cancer, but it commonly causes severe diarrhea that can interrupt treatment. This study tests whether taking probiotics โ beneficial bacteria that support gut health โ can reduce or prevent this side effect. Researchers will compare women who receive probiotics with those who receive a placebo (an inactive pill), and all participants will also receive standard anti-diarrhea medication.
Severe diarrhea from this medication causes many patients to skip doses, reduce their dose, or stop treatment entirely, which can impact how well the cancer therapy works. Early evidence suggests that probiotics might help by supporting a healthy gut microbiome, but doctors don't yet know if this actually prevents diarrhea from this specific medication.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be randomly assigned to receive either probiotics or a placebo pill while taking neratinib and standard anti-diarrhea medication for six weeks (two treatment cycles). During this time, you'll have clinic visits for check-ups and to provide stool samples so researchers can study your gut bacteria and how it changes. The study team will closely monitor your side effects and how well the treatment is working for your cancer.
AI-generated summary from trial data ยท Jun 24, 2026 ยท Not medical advice
China